These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 12209976)

  • 1. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Int J Cancer; 2002 Sep; 101(3):253-8. PubMed ID: 12209976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.
    van Kuilenburg AB; Muller EW; Haasjes J; Meinsma R; Zoetekouw L; Waterham HR; Baas F; Richel DJ; van Gennip AH
    Clin Cancer Res; 2001 May; 7(5):1149-53. PubMed ID: 11350878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.
    Van Kuilenburg AB; Meinsma R; Zoetekouw L; Van Gennip AH
    Pharmacogenetics; 2002 Oct; 12(7):555-8. PubMed ID: 12360106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB; De Abreu RA; van Gennip AH
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
    Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
    Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Severe toxicity after treatment with capecitabine and fluorouracil due to partial dihydropyrimidine dehydrogenase deficiency].
    Hooiveld EA; van Kuilenburg AB; Haanen JB; Westermann AM
    Ned Tijdschr Geneeskd; 2004 Mar; 148(13):626-8. PubMed ID: 15083629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
    Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?].
    Coriat R; Chaussade S
    Therapie; 2007; 62(2):105-9. PubMed ID: 17582310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of IVS14+ 1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer.
    Uzunkoy A; Dilmec F; Ozgonul A; van Kuilenburg AB; Akkafa F
    Anticancer Res; 2007; 27(6B):3899-902. PubMed ID: 18225548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Saif MW; Ezzeldin H; Vance K; Sellers S; Diasio RB
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):503-7. PubMed ID: 17165084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput genotyping by DHPLC of the dihydropyrimidine dehydrogenase gene implicated in (fluoro)pyrimidine catabolism.
    Gross E; Seck K; Neubauer S; Mayr J; Hellebrand H; Ratanaphan A; Lutz V; Stockinger H; Kiechle M
    Int J Oncol; 2003 Feb; 22(2):325-32. PubMed ID: 12527930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
    Omura K
    Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
    Paré L; Paez D; Salazar J; Del Rio E; Tizzano E; Marcuello E; Baiget M
    Br J Clin Pharmacol; 2010 Aug; 70(2):268-72. PubMed ID: 20653680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
    Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
    Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy.
    Ciccolini J; Mercier C; Evrard A; Dahan L; Boyer JC; Duffaud F; Richard K; Blanquicett C; Milano G; Blesius A; Durand A; Seitz JF; Favre R; Lacarelle B
    Ther Drug Monit; 2006 Oct; 28(5):678-85. PubMed ID: 17038885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine.
    Cerić T; Obralić N; Kapur-Pojskić L; Macić D; Beslija S; Pasić A; Cerić S
    Bosn J Basic Med Sci; 2010 May; 10(2):133-9. PubMed ID: 20507294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.